Pascale Soyeux
Overview
Explore the profile of Pascale Soyeux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Majidipur A, Morin-Dewaele M, Gaspar Lopes J, Berry F, Fouchet J, Bartier S, et al.
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36834705
In early 2020, the novel pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, and rapidly propagated worldwide causing a global health emergency. SARS-CoV-2 binds to the...
2.
Blanc C, Moktefi A, Jolly A, De La Grange P, Gay D, Nicolaiew N, et al.
Br J Cancer
. 2022 Dec;
128(5):918-927.
PMID: 36550208
Background: Neuroendocrine prostate cancer (NEPC) is a multi-resistant variant of prostate cancer (PCa) that has become a major challenge in clinics. Understanding the neuroendocrine differentiation (NED) process at the molecular...
3.
Masson-Lecomte A, Maille P, Pineda S, Soyeux P, Sagrera A, Rava M, et al.
Bladder Cancer
. 2022 Sep;
5(2):159-169.
PMID: 36157135
Background: Major interest lies in the evaluation of immune infiltrate in bladder cancer. CD8+ cytotoxic lymphocytes are key effectors of adaptive immune response. Objectives: The aims of the study were...
4.
Firlej V, Soyeux P, Nourieh M, Huet E, Semprez F, Allory Y, et al.
Int J Mol Sci
. 2022 May;
23(9).
PMID: 35562881
Prostate cancer (PCa) is the second most frequent cancer and the fifth leading cause of cancer death in men worldwide. If local PCa presents a favorable prognosis, available treatments for...
5.
Moktefi A, Pouessel D, Liu J, Sirab N, Maille P, Soyeux P, et al.
Mod Pathol
. 2018 Feb;
31(8):1270-1281.
PMID: 29467478
Although human epidermal growth factor receptor 2 (HER2) may represent a therapeutic target, its evaluation in urothelial carcinoma of the bladder does not rely on a standardized scoring system by...
6.
Destouches D, Sader M, Terry S, Marchand C, Maille P, Soyeux P, et al.
Oncotarget
. 2016 Mar;
7(43):69397-69411.
PMID: 26993766
Despite the advent of several new treatment options over the past years, advanced/metastatic prostate carcinoma (PCa) still remains incurable, which justifies the search for novel targets and therapeutic molecules. Nucleophosmin...
7.
Terry S, Nicolaiew N, Basset V, Semprez F, Soyeux P, Maille P, et al.
Cancer
. 2015 Feb;
121(9):1422-30.
PMID: 25639219
Background: In view of the marked molecular heterogeneity of prostate cancer (PCa), clinical and pathologic parameters alone may be unreliable for predicting disease outcomes after surgical intervention. The development of...
8.
Rebouissou S, Bernard-Pierrot I, De Reynies A, Lepage M, Krucker C, Chapeaublanc E, et al.
Sci Transl Med
. 2014 Jul;
6(244):244ra91.
PMID: 25009231
Muscle-invasive bladder carcinoma (MIBC) constitutes a heterogeneous group of tumors with a poor outcome. Molecular stratification of MIBC may identify clinically relevant tumor subgroups and help to provide effective targeted...
9.
Calderaro J, Rebouissou S, De Koning L, Masmoudi A, Herault A, Dubois T, et al.
Int J Cancer
. 2013 Oct;
134(8):1776-84.
PMID: 24122582
The PI3K/AKT pathway is considered to play a major role in bladder carcinogenesis, but its relationships with other molecular alterations observed in bladder cancer remain unknown. We investigated PI3K/AKT pathway...
10.
Terry S, Maille P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, et al.
Neoplasia
. 2013 Jul;
15(7):761-72.
PMID: 23814488
Castration-resistant prostate cancers (CRPCs) that relapse after androgen deprivation therapies (ADTs) are responsible for the majority of mortalities from prostate cancer (PCa). While mechanisms enabling recurrent activity of androgen receptor...